graph EGM comparisons
pembrolizumab (10mg/kg)titleIpilimumab (10 mg/kg)titleipilimumab plus gp100titlepembrolizumab plus SoCtitlenivolumab alonetitlepembrolizumab (10mg/kg) 2 weekstitlepembrolizumab (2mg/kg)titleipilimumab alonetitleipilimumab plus SoCtitleplacebo plus SoCtitleStandard of Care (SoC)titlegp100titleCA184-004, 2011 NCT00261365 mML - L2 - all population 40/42Ascierto (ipi 10 vs 3 mg/kg), 2017 NCT01515189 mML - L2 - all population 365/362MDX010 Ipi vs gp100, 2010 NCT00094653 mML - L2 - all population 137/136MDX010 Ipi plus gp100 vs gp100, 2010 NCT00094653 mML - L2 - all population 403/136MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 NCT00094653 mML - L2 - all population 403/137CA184-024, 2011 NCT00324155 mML - L2 - all population 250/252CheckMate 037, 2015 NCT01721746 mML - L2 - all population 272/133KEYNOTE-006 (3 week), 2015 NCT01866319 mML - L2 - all population 277/278KEYNOTE-002 (10 mg/kg), 2015 NCT01704287 mML - L2 - all population 181/179KEYNOTE-006 (2 week), 2015 NCT01866319 mML - L2 - all population 279/278KEYNOTE-002 (2 mg/kg), 2015 NCT01704287 mML - L2 - all population 180/179KEYNOTE-022, 2019 NCT02130466 mML - L2 - BRAF mutant 60/60

Pathology:  mML - L2 - all population;   mML - L2 - BRAF mutant; 

mML - L2 - all populationmML - L2 - BRAF mutant
CA184-004, 2011Ascierto (ipi 10 vs 3 mg/kg), 2017MDX010 Ipi vs gp100, 2010MDX010 Ipi plus gp100 vs gp100, 2010MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010CA184-024, 2011CheckMate 037, 2015KEYNOTE-006 (3 week), 2015KEYNOTE-002 (10 mg/kg), 2015KEYNOTE-006 (2 week), 2015KEYNOTE-002 (2 mg/kg), 2015KEYNOTE-022, 2019
pembrolizumab (10mg/kg)2T1T1
Ipilimumab (10 mg/kg)2T1T1
ipilimumab plus gp1002T1T1
pembrolizumab plus SoC1T1
nivolumab alone1T1
pembrolizumab (10mg/kg) 2 weeks1T1
pembrolizumab (2mg/kg)1T1
ipilimumab alone1T0T0T1T0T0T0
ipilimumab plus SoC1T1
placebo plus SoC0T0T0
Standard of Care (SoC)0T0T0T0
gp1000T0T0